Li Qian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Qian has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Tao Yang
Department of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University, China
4 shared publications Kuanfeng Xu
First Affiliated Hospital of Nanjing Medical University
3 shared publicationsLiping Yu
Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA
3 shared publicationsXinyu Xu
First Affiliated Hospital of Nanjing Medical University
3 shared publications- Yu Liu
Department of Endocrinology, Sir Run Run Hospital, Nanjing Medical University
3 shared publications Guofeng Wang
Department of Endocrinology The First People's Hospital of Lianyungang Lianyungang China
2 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Wiley in Journal of Diabetes
- Vol. 18 (7) , e70255
Effect of Topical Application of Antimicrobial Peptide PL ‐5 (Peceleganan) Spray on Mild to Moderate Infection of Diabetic Foot Ulcers: A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled Clinical Trial
Aims: To evaluate the clinical efficacy and safety of topical antimicrobial peptide PL‐5 (Peceleganan) spray combined with standard debridement in the treatment of mildly to moderately infected diabetic foot ulcers (DFUs). Materials and Methods: This multicenter, randomized, double‐blind, placebo‐controlled trial was conducted in four tertiary hospitals. Eligible patients were randomized to PL‐5 spray or placebo, both receiving standardized debridement. The primary endpoint was clinical response rate at 1 day after end of treatment (EOT1). Results: Baseline characteristics were balanced between groups. The clinical response rate at EOT1 was significantly higher in the PL‐5 group than in the placebo group ( p < 0.05). The clearance rate of drug‐resistant bacteria at EOT1 was 71.43% in the PL‐5 group versus 50% in the control group ( p < 0.05). No significant differences were observed in overall microbiological eradication rates at EOT1 (57.89% vs. 33.33%) or EOT7 (64.71% vs. 40.00%) (both p > 0.05). Adverse event rates were 24.24% in the PL‐5 group and 33.33% in the placebo group ( p > 0.05), with no serious drug‐related adverse events. PL‐5 showed a significant improvement in clinical effective rate, but overall microbiological eradication was not significantly different between groups. However, in the subset of patients with drug‐resistant bacteria, PL‐5 demonstrated a significantly higher clearance rate, suggesting potential for treatment of resistant infections. Conclusions: Topical PL‐5 spray improves clinical outcomes in mild‐to‐moderate infected diabetic foot ulcers and achieves superior pathogen clearance among drug‐resistant infection subgroups. It represents a promising low‐resistance topical option for managing mild to moderate DFU infections. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2300068632
- 27 July 2026
- Published by Wiley in Journal of Diabetes
- Vol. 18 (7) , e70255
Open AccessEffect of Topical Application of Antimicrobial Peptide PL ‐5 (Peceleganan) Spray on Mild to Moderate Infection of Diabetic Foot Ulcers: A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled Clinical Trial
Aims: To evaluate the clinical efficacy and safety of topical antimicrobial peptide PL‐5 (Peceleganan) spray combined with standard debridement in the treatment of mildly to moderately infected diabetic foot ulcers (DFUs). Materials and Methods: This multicenter, randomized, double‐blind, placebo‐controlled trial was conducted in four tertiary hospitals. Eligible patients were randomized to PL‐5 spray or placebo, both receiving standardized debridement. The primary endpoint was clinical response rate at 1 day after end of treatment (EOT1). Results: Baseline characteristics were balanced between groups. The clinical response rate at EOT1 was significantly higher in the PL‐5 group than in the placebo group ( p < 0.05). The clearance rate of drug‐resistant bacteria at EOT1 was 71.43% in the PL‐5 group versus 50% in the control group ( p < 0.05). No significant differences were observed in overall microbiological eradication rates at EOT1 (57.89% vs. 33.33%) or EOT7 (64.71% vs. 40.00%) (both p > 0.05). Adverse event rates were 24.24% in the PL‐5 group and 33.33% in the placebo group ( p > 0.05), with no serious drug‐related adverse events. PL‐5 showed a significant improvement in clinical effective rate, but overall microbiological eradication was not significantly different between groups. However, in the subset of patients with drug‐resistant bacteria, PL‐5 demonstrated a significantly higher clearance rate, suggesting potential for treatment of resistant infections. Conclusions: Topical PL‐5 spray improves clinical outcomes in mild‐to‐moderate infected diabetic foot ulcers and achieves superior pathogen clearance among drug‐resistant infection subgroups. It represents a promising low‐resistance topical option for managing mild to moderate DFU infections. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2300068632
- Open Access
- 24 October 2022
- Published by Bioscientifica in Endocrine Connections
- Vol. 11 (12)
Prevalence of antibodies targeting ubiquitin-conjugating enzyme 2L3 and eukaryote translation elongation factor 1 α1 in Chinese Han and American Caucasian populations with type 1 diabetes
We assessed the prevalence of two novel islet autoantibodies, those targeting ubiquitin-conjugating enzyme 2L3 (UBE2L3) and eukaryote translation elongation factor 1 α1 (eEF1A1), in type 1 diabetes mellitus (T1DM) to evaluate their utility in T1DM diagonsis with comparison to other islet autoantibodies. We also aimed to determined whether age and ethnicity impacted their diagnostic value. Electrochemiluminescence (ECL) assay was used to detect UBE2L3-Ab and eEF1A1-Ab in 193 Chinese Han and 570 American Caucasian subjects with T1DM, 282 Chinese Han and 199 American Caucasian controls. In Chinese and American cohorts, the UBE2L3-Ab cut-off indices were 0.039 and 0.038, and the eEF1A1-Ab cut-off indices were 0.048 and 0.050, respectively. The prevalence of UBE2L3-Ab was significantly higher in the Chinese (9.33%) and American(3.86%) subjects with T1DM than in the controls (p<0.05). The prevalence of UBE2L3-Ab in T1DM were significantly higher in Chinese than in American (p<0.05). Albeit not statistically significant, the prevalence of UBE2L3-Ab in T1DM was slightly higher in children than in adults in both ethnicity. The differences in eEF1A1-Ab levels between subjects with T1DM and controls was not significant. Meanwhile, all American subjects with UBE2L3-Ab also harbored GADA or IAA. In contrast, 2.07% of the Chinese subjects with UBE2L3-Ab positive were previously classified as autoantibody-negative based on GADA and IAA. So the prevalence of UBE2L3-Ab in T1DM patients was significantly higher than in controls and was variable according to ethnicity as well as tend to be higher in children than adults. However, UBE2L3-Ab and eEF1A1-Ab may not reliable diagnostic biomarker for T1DM.
- 24 October 2022
- Published by Bioscientifica in Endocrine Connections
- Vol. 11 (12)
Open AccessPrevalence of antibodies targeting ubiquitin-conjugating enzyme 2L3 and eukaryote translation elongation factor 1 α1 in Chinese Han and American Caucasian populations with type 1 diabetes
We assessed the prevalence of two novel islet autoantibodies, those targeting ubiquitin-conjugating enzyme 2L3 (UBE2L3) and eukaryote translation elongation factor 1 α1 (eEF1A1), in type 1 diabetes mellitus (T1DM) to evaluate their utility in T1DM diagonsis with comparison to other islet autoantibodies. We also aimed to determined whether age and ethnicity impacted their diagnostic value. Electrochemiluminescence (ECL) assay was used to detect UBE2L3-Ab and eEF1A1-Ab in 193 Chinese Han and 570 American Caucasian subjects with T1DM, 282 Chinese Han and 199 American Caucasian controls. In Chinese and American cohorts, the UBE2L3-Ab cut-off indices were 0.039 and 0.038, and the eEF1A1-Ab cut-off indices were 0.048 and 0.050, respectively. The prevalence of UBE2L3-Ab was significantly higher in the Chinese (9.33%) and American(3.86%) subjects with T1DM than in the controls (p<0.05). The prevalence of UBE2L3-Ab in T1DM were significantly higher in Chinese than in American (p<0.05). Albeit not statistically significant, the prevalence of UBE2L3-Ab in T1DM was slightly higher in children than in adults in both ethnicity. The differences in eEF1A1-Ab levels between subjects with T1DM and controls was not significant. Meanwhile, all American subjects with UBE2L3-Ab also harbored GADA or IAA. In contrast, 2.07% of the Chinese subjects with UBE2L3-Ab positive were previously classified as autoantibody-negative based on GADA and IAA. So the prevalence of UBE2L3-Ab in T1DM patients was significantly higher than in controls and was variable according to ethnicity as well as tend to be higher in children than adults. However, UBE2L3-Ab and eEF1A1-Ab may not reliable diagnostic biomarker for T1DM.
- Open Access
- 1 January 2020
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 44 (2) , 260-266
Glutamic Acid Decarboxylase Autoantibody Detection by Electrochemiluminescence Assay Identifies Latent Autoimmune Diabetes in Adults with Poor Islet Function
Zhu Y, et al. Diabetes Metab J. 2019 Jan;43:e61. https://doi.org/10.4093/dmj.2019.0007
- 1 January 2020
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 44 (2) , 260-266
Open AccessGlutamic Acid Decarboxylase Autoantibody Detection by Electrochemiluminescence Assay Identifies Latent Autoimmune Diabetes in Adults with Poor Islet Function
Zhu Y, et al. Diabetes Metab J. 2019 Jan;43:e61. https://doi.org/10.4093/dmj.2019.0007
- Open Access
- 25 May 2016
- Published by Springer Nature in Science China Life Sciences
- Vol. 59 (9) , 930-939
The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients
Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobinA1c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1DM patients (duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus.
- 25 May 2016
- Published by Springer Nature in Science China Life Sciences
- Vol. 59 (9) , 930-939
Open AccessThe heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients
Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobinA1c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1DM patients (duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus.
- Open Access
- 1 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e58939
UCP2 -866G/A, Ala55Val and UCP3 -55C/T Polymorphisms in Association with Obesity Susceptibility — A Meta-Analysis Study
Variants of UCP2 and UCP3 genes have been reported to be associated with obesity, but the available data on the relationship are inconsistent. A meta-analysis was performed to determine whether there are any associations between the UCP2 -866G/A, Ala55Val, and UCP3 -55C/T polymorphisms and obesity susceptibility. The PubMed, Embase, Web of Science and CNKI, CBMdisc databases were searched for all relevant case-control studies. The fixed or random effect pooled measure was determined on the bias of heterogeneity test among studies. Publication bias was examined by the modified Begg's and Egger's test. Twenty-two published articles with thirty-two outcomes were included in the meta-analysis: 12 studies with a total of 7,390 cases and 9,860 controls were analyzed for UCP2 -866G/A polymorphism with obesity, 9 studies with 1,483 cases and 2,067 controls for UCP2 Ala55Val and 8 studies with 2,180 cases and 2,514 controls for UCP3 -55C/T polymorphism. Using an additive model, the UCP2 -866G/A polymorphism showed no significant association with obesity risk in Asians (REM OR = 0.81, 95% CI: 0.65–1.01). In contrast, a statistically significant association was observed in subjects of European descent (FEM OR = 1.06, 95% CI: 1.01–1.12). But neither the UCP2 Ala55Val nor the UCP3 -55C/T polymorphism showed any significant association with obesity risk in either subjects of Asian (REM OR = 0.84, 95% CI: 0.67–1.06 for Ala55Val; REM OR = 0.94, 95% CI: 0.55–1.28 for -55C/T) or of European descent (REM OR = 1.04, 95% CI: 0.80-1.36 for Ala55Val; FEM OR = 1.08, 95% CI: 0.97–1.20 for -55C/T). Our meta-analysis revealed that the UCP2 -866G/A polymorphism may be a risk factor for susceptibility to obesity in subjects of European descent, but not in individuals of Asian descent. And our results did not support the association between UCP2 Ala55Val, UCP3 -55C/T polymorphisms and obesity in the populations investigated. This conclusion warrants confirmation by further studies.
- 1 April 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4) , e58939
Open AccessUCP2 -866G/A, Ala55Val and UCP3 -55C/T Polymorphisms in Association with Obesity Susceptibility — A Meta-Analysis Study
Variants of UCP2 and UCP3 genes have been reported to be associated with obesity, but the available data on the relationship are inconsistent. A meta-analysis was performed to determine whether there are any associations between the UCP2 -866G/A, Ala55Val, and UCP3 -55C/T polymorphisms and obesity susceptibility. The PubMed, Embase, Web of Science and CNKI, CBMdisc databases were searched for all relevant case-control studies. The fixed or random effect pooled measure was determined on the bias of heterogeneity test among studies. Publication bias was examined by the modified Begg's and Egger's test. Twenty-two published articles with thirty-two outcomes were included in the meta-analysis: 12 studies with a total of 7,390 cases and 9,860 controls were analyzed for UCP2 -866G/A polymorphism with obesity, 9 studies with 1,483 cases and 2,067 controls for UCP2 Ala55Val and 8 studies with 2,180 cases and 2,514 controls for UCP3 -55C/T polymorphism. Using an additive model, the UCP2 -866G/A polymorphism showed no significant association with obesity risk in Asians (REM OR = 0.81, 95% CI: 0.65–1.01). In contrast, a statistically significant association was observed in subjects of European descent (FEM OR = 1.06, 95% CI: 1.01–1.12). But neither the UCP2 Ala55Val nor the UCP3 -55C/T polymorphism showed any significant association with obesity risk in either subjects of Asian (REM OR = 0.84, 95% CI: 0.67–1.06 for Ala55Val; REM OR = 0.94, 95% CI: 0.55–1.28 for -55C/T) or of European descent (REM OR = 1.04, 95% CI: 0.80-1.36 for Ala55Val; FEM OR = 1.08, 95% CI: 0.97–1.20 for -55C/T). Our meta-analysis revealed that the UCP2 -866G/A polymorphism may be a risk factor for susceptibility to obesity in subjects of European descent, but not in individuals of Asian descent. And our results did not support the association between UCP2 Ala55Val, UCP3 -55C/T polymorphisms and obesity in the populations investigated. This conclusion warrants confirmation by further studies.